Market Cap: $100.18B
SA
Sanofi
SNY
NASDAQ (NASDAQ Global Select)USD
Market Cap: $100.18B
Sanofi (Ticker: SNY) partners with the Department of Health in Abu Dhabi to enhance global vaccine innovation through a new initiative. They sign a Memorandum of Understanding (MoU) to establish a Vac…
On June 23, 2026, Sanofi (Ticker: SNY) and the Department of Health – Abu Dhabi (DoH) formalize their partnership to drive vaccine innovation through the signing of a Memorandum of Understanding. This…
Sanofi (Ticker: SNY) takes a substantial step in pediatric healthcare by expanding the use of its therapy to treat younger patients, reinforcing its dedication to addressing unmet medical needs. This…
Sanofi (Ticker: SNY) expands the use of its therapy for pediatric patients, demonstrating its commitment to meeting the medical needs of younger populations. This significant decision is backed by pos…
Sanofi (Ticker: SNY) announces its decision to discontinue the Phase 3 MOBILIZE study, which evaluated riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not…
Sanofi's Breakthrough in COPD Treatment: Tozorakimab's Revolutionary Approach Sanofi stands at the forefront of respiratory disease management with its latest innovation, Tozorakimab, a monoclonal ant…
Sanofi Expands Immunology Portfolio Through Partnership with Kali Therapeutics Sanofi enhances its foothold in immunology with a licensing agreement for KT501, an innovative tri-specific T-cell engage…
Federal Court Critiques U.S. Vaccine Advisory Practices: Implications for Public Health Policy In a significant legal development, a federal court raises concerns regarding recent actions by the U.S.…
Legal Accountability in Public Health Policies: A Turning Point for Vaccine Governance Recent rulings by a federal court spotlight significant concerns about the U.S. government's handling of vaccinat…
Strategic Positioning in Biotech: AstraZeneca’s Pursuit of Abivax In recent developments in the biotech sector, AstraZeneca Plc emerges as a leading candidate for the acquisition of French biotechnolo…
AstraZeneca's Strategic Acquisition Moves Highlight Industry Dynamics In a significant development within the biotechnology sector, British drugmaker AstraZeneca Plc emerges as a leading candidate for…
AstraZeneca Targets Abivax: A Strategic Move in Biotech Recent developments in the biotech industry spotlight AstraZeneca Plc as it emerges as a leading contender for the acquisition of French biotech…
A Breakthrough Therapy: AYVAKIT® Enhances Quality of Life for Patients with Indolent Systemic Mastocytosis Blueprint Medicines, a subsidiary of Sanofi, showcases groundbreaking advancements in the tre…
### Sanofi’s Shifting Investor Sentiment Marks a Positive Trend Sanofi SA is witnessing a significant shift in investor sentiment as the company reports a 5.13% decline in short interest within the la…
Sanofi’s AYVAKIT® Therapy Demonstrates Efficacy for Systemic Mastocytosis Patients Sanofi’s Blueprint Medicines recently presents compelling data from its four-year PIONEER clinical study on AYVAKIT®…
Sanofi's Position Amidst Competitive Pressures in Biopharmaceuticals In the competitive landscape of biopharmaceuticals, Sanofi remains acutely aware of the challenges that companies like Regeneron Ph…
Navigating Competitive Waters: Regeneron's Struggles Amidst Industry Challenges Regeneron Pharmaceuticals finds itself at a critical juncture as it faces significant challenges in maintaining its mark…
Pharma pivoting to speed oncology antibodies and simplify delivery Regulatory accelerants and subcutaneous delivery are reshaping how big drugmakers advance antibody therapies, a shift that is closely…
Sanofi names Manuela Buxo to lead Specialty Care and Dupixent strategy Sanofi appoints Manuela Buxo as head of its Specialty Care Global Business Unit, effective March 1, 2026, with Buxo joining the c…
Sanofi names Manuela Buxo to lead Specialty Care global push Building on Dupixent momentum: continuity at the top of Specialty Care Sanofi appoints Manuela Buxo as Head of Specialty Care, effective Ma…
Sanofi signs on to TrumpRx push to sell medicines directly to consumers Sanofi is among major drugmakers that the White House says commit to the Trump administration’s new TrumpRx programme, a direct-…
White House unveils TrumpRx with Sanofi among signatories Sanofi is among a group of drugmakers that the White House says commit to steep discounts under the administration’s new TrumpRx program, whic…
White House launches TrumpRx, naming major drugmakers including Sanofi The White House is unveiling a new direct-to-consumer prescription drug initiative called TrumpRx that several major pharmaceutic…
Sanofi's Commitment to Innovation Amid Global Challenges Sanofi continues to solidify its position in the biopharmaceutical industry, focusing on innovation in response to evolving healthcare demands.…
Sanofi's Strategic Focus Amid Global Economic Uncertainty In the face of significant geopolitical tensions and economic volatility, Sanofi navigates a complex landscape that impacts its operations and…